Press Releases

    Print Page  Close Window
BioMed Realty Expands Leadership Position In Seattle's South Lake Union Innovation District With $90 Million Investment In Core Life Science Research Facility
The 116,200 Square Foot Class A Laboratory and Office Facility Serves as the Headquarters and Primary Research Center for World Renowned Seattle Biomedical Research Institution

SAN DIEGO, Feb. 3, 2015 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that it is under contract to acquire the 307 Westlake Avenue North building in the heart of the burgeoning South Lake Union life science market of Seattle, Washington for approximately $90 million. This strategic investment continues the momentum in Seattle for BioMed Realty, which last year broke ground just a few blocks away on a 121,000 square foot expansion of its BioMed Realty Research Center. The company will own nearly 500,000 square feet of laboratory and office space in the core innovation districts of downtown Seattle.

307 Westlake Avenue North, Seattle, WA

The five-story 307 Westlake Avenue North building is 99% leased to four tenants, including approximately 84,800 square feet which serves as the headquarters and research facility for Seattle Biomedical Research Institution (Seattle BioMed). The property also serves as the home to Juno Therapeutics, a clinical-stage company developing immunotherapies for cancer treatment which completed its IPO in December 2014.

Founded in 1976, Seattle BioMed is Seattle's first global health organization that continues to be a leader in the Seattle life science community. This groundbreaking research organization implements a revolutionary systems biology approach to infectious disease research with its nearly 250 staff members. Seattle BioMed has done groundbreaking research, including work on a malaria vaccine in partnership with the Bill and Melinda Gates Foundation and Fred Hutchinson Cancer Research Center and has made significant progress on a vaccine for the HIV virus.  

With BioMed Realty's stewardship, the 307 Westlake research facility will continue to anchor and support Seattle's vibrant life science community at the intersection of the growing health care industry and the permanent frontier of innovation.

BioMed Realty has built its business in Seattle and around the country on strong relationships with its tenant partners. Seattle BioMed adds to the company's strong Seattle tenant list, which includes Novo Nordisk, Omeros and NanoString. In addition, through this transaction, Seattle BioMed joins the company's growing list of partnerships with world-class research organizations including the Broad Institute, The J. Craig Venter Institute, the Wyss Institute and the Salk Institute, and relationships in the University research community, including Harvard University, Yale University, the University of Pennsylvania, Wake Forest University, Washington University and University of CaliforniaSan Diego.

"We are very pleased to be expanding our footprint in Seattle's core innovation district of South Lake Union, one of the fastest growing, most exciting life science communities in the country," said Mike Ruhl, Senior Director of Leasing and Development for BioMed Realty in Seattle. "As the leading life science real estate company in Seattle, acquiring this state-of-the-art building at 307 Westlake allows us to provide Seattle's growing life science industry with Class A laboratory and office space right in the middle of Seattle's innovation center, with tremendous neighborhood amenities, including a growing offering of shops and restaurants."

The critically important project is located in the heart of the transformed South Lake Union innovation district in close proximity to the region's most esteemed research institutes, including the Gates Foundation, Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, the University of Washington's School of Medicine, the Children's Research Institute, the Institute for Systems Biology, PATH and the Group Health Research Institute. 

Alan Gold, the company's Chairman and Chief Executive Officer, noted, "In December 2014, we completed the sale of our 9911 Belward Campus Drive property in Rockville, Maryland, for $322.5 million so that we might invest those proceeds in higher growth investment opportunities. Our recently announced 360,000 square foot build-to-suit development for Illumina in the Bay Area and this acquisition of 307 Westlake in the heart of the South Lake Union innovation district are very compelling high quality growth opportunities."

This acquisition is slated to close in the first quarter of 2015. The acquisition is subject to customary closing conditions, and BioMed Realty can offer no assurances that the acquisition will close on the terms described herein, or at all.

About BioMed Realty Trust

BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 17.5 million rentable square feet.  Additional information is available at Follow us on Twitter @biomedrealty.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: the possibility that  the company's acquisition of the 307 Westlake Avenue North property may not occur on the terms described herein, or at all; failure to manage effectively the company's growth and expansion into new markets, or to integrate acquisitions successfully, including the acquisition of the 307 Westlake Avenue North property in Seattle, Washington; and general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate). For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Photo -


To view the original version on PR Newswire, visit:

SOURCE BioMed Realty Trust, Inc.

Jim Cullinan, Vice President, Marketing, (858) 753-8661,